JP7528080B2 - 痛風または高尿酸血症を処置または予防するための方法 - Google Patents

痛風または高尿酸血症を処置または予防するための方法 Download PDF

Info

Publication number
JP7528080B2
JP7528080B2 JP2021531034A JP2021531034A JP7528080B2 JP 7528080 B2 JP7528080 B2 JP 7528080B2 JP 2021531034 A JP2021531034 A JP 2021531034A JP 2021531034 A JP2021531034 A JP 2021531034A JP 7528080 B2 JP7528080 B2 JP 7528080B2
Authority
JP
Japan
Prior art keywords
compound
effective amount
therapeutically effective
administered
dibromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531034A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020118114A5 (https=
JP2022510303A (ja
JP2022510303A5 (https=
Inventor
ヤン，シュンチー
イェー，リテイン
ヤン，ロンズ
Original Assignee
アースローシ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アースローシ セラピューティクス，インク． filed Critical アースローシ セラピューティクス，インク．
Publication of JP2022510303A publication Critical patent/JP2022510303A/ja
Publication of JPWO2020118114A5 publication Critical patent/JPWO2020118114A5/ja
Publication of JP2022510303A5 publication Critical patent/JP2022510303A5/ja
Application granted granted Critical
Publication of JP7528080B2 publication Critical patent/JP7528080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
JP2021531034A 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための方法 Active JP7528080B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776251P 2018-12-06 2018-12-06
US62/776,251 2018-12-06
PCT/US2019/064785 WO2020118114A1 (en) 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia

Publications (4)

Publication Number Publication Date
JP2022510303A JP2022510303A (ja) 2022-01-26
JPWO2020118114A5 JPWO2020118114A5 (https=) 2022-12-12
JP2022510303A5 JP2022510303A5 (https=) 2022-12-12
JP7528080B2 true JP7528080B2 (ja) 2024-08-05

Family

ID=70974386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531034A Active JP7528080B2 (ja) 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための方法

Country Status (12)

Country Link
US (1) US12419854B2 (https=)
EP (1) EP3890722A4 (https=)
JP (1) JP7528080B2 (https=)
CN (1) CN113164439A (https=)
AU (1) AU2019392750B2 (https=)
BR (1) BR112021010720A2 (https=)
CA (1) CA3121624A1 (https=)
EA (1) EA202191543A1 (https=)
IL (1) IL283665A (https=)
SG (1) SG11202105743RA (https=)
TW (1) TW202038936A (https=)
WO (1) WO2020118114A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3484862B1 (en) 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
SG11202105743RA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
TW202330485A (zh) * 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
WO2018017368A1 (en) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
WO2005121112A1 (ja) 2004-06-10 2005-12-22 Torii Pharmaceutical Co., Ltd. ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) * 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2013152860A2 (en) 2012-04-11 2013-10-17 Dutalys Gmbh Improved antibody light chains
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104717980A (zh) 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
JP2016500367A (ja) 2012-12-05 2016-01-12 デュタリス ゲーエムベーハー デュアルターゲティング
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
WO2014194226A2 (en) 2013-05-31 2014-12-04 Takeda Pharmaceuticals U.S.A., Inc. Methods of treatment and compositions with xanthine oxidase inhibitors
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
CN107001356B (zh) 2014-07-31 2019-09-03 默克专利有限公司 用于神经退化性疾病的中氮茚衍生物
CN104262305B (zh) 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516B (zh) 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
KR101964435B1 (ko) 2016-12-14 2019-04-01 주식회사 엘지화학 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
US20210130312A1 (en) 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
MX2021003845A (es) 2018-10-01 2021-05-27 Astrazeneca Ab Composiciones para reducir el acido urico serico.
SG11202105743RA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
WO2020232156A1 (en) 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia
CN112952564B (zh) 2019-12-25 2022-04-22 华为数字能源技术有限公司 配电模块及通信电源系统
KR20230024354A (ko) 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
TW202330485A (zh) 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
WO2023125667A1 (en) 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
WO2018017368A1 (en) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Also Published As

Publication number Publication date
KR20210102933A (ko) 2021-08-20
EP3890722A4 (en) 2022-08-24
WO2020118114A1 (en) 2020-06-11
BR112021010720A2 (pt) 2021-08-31
AU2019392750B2 (en) 2025-07-10
CA3121624A1 (en) 2020-06-11
EP3890722A1 (en) 2021-10-13
IL283665A (en) 2021-07-29
AU2019392750A1 (en) 2021-07-15
US20220023251A1 (en) 2022-01-27
JP2022510303A (ja) 2022-01-26
EA202191543A1 (ru) 2021-10-26
SG11202105743RA (en) 2021-06-29
TW202038936A (zh) 2020-11-01
CN113164439A (zh) 2021-07-23
US12419854B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
JP2025026857A (ja) 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
US20250066316A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
KR102956127B1 (ko) 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
US12612401B2 (en) Crystalline forms of an S1P receptor modulator
US20240010654A1 (en) Crystalline forms of a tyk2 inhibitor
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態
HK40060723A (en) Compound for treating gout or hyperuricemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221202

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240724

R150 Certificate of patent or registration of utility model

Ref document number: 7528080

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150